{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 64,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes flow cytometry plots and bar charts showing efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/8",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.4,
        "y": 0.45
      },
      "kind": "chart",
      "text": "IFNy (pg/mL) for NT vs NXC-201",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d103e03e-c992-48d9-ac11-529e0349a10f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "chart",
      "text": "BCMA Expression (MFI) in AL patients",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f02d8281-5f7b-4306-bec7-f130c3c699d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.7,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Flow cytometry showing elimination of CD138++CD38++ cells",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecab2ea4-57db-4a41-b7e4-34eb6064ad37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "list",
      "text": "a) Uneven BCMA expression and b) frail patient condition has historically prevented conventional, approved CAR-T use in AL Amyloidosis\nNXC-201 was designed and tested for human AL Amyloidosis treatment, with preclinical testing revealing that:",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af45bfe1-fb63-4854-831e-f5fbc656264e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "NXC-201's uniquely favorable tolerability profile (no neurotoxicity + “Single-day CRS”) combined with proven preclinical and clinical efficacy make NXC-201 uniquely suited to treat AL Amyloidosis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61a46527-a07d-4452-98e9-3bc6022cc6aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Note: NXC-201 (formerly NBI0101). Infy TNFa for two patients, AL1, AL2. Far right top right quartile selected diseased AL Amyloidosis plasma cell elimination. Far right graph after 33 days co-incubated with NXC-201. Source: Kfir-Erenfeld S, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5848ece4-7478-4bc3-838d-ee8917f4cd8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.08
      },
      "kind": "title",
      "text": "All BCMA CAR-Ts Are Not Created Equal",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3616313-9afd-48ff-9989-92d53ac4324a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 designed for high activity against disease-causing AL Amyloidosis plasma cells",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c78a3f4-9010-4455-8e0c-f50025164442",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "908405ae-68fc-4e65-b2a0-37525de33e25",
      "evidence": "Flow cytometry showing elimination of CD138++CD38++ cells",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "c962cea8-102a-4bc7-8d0f-aa1442fcfcf5",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 7-8 highlight the problem of neurotoxicity in CAR-T therapies and its impact on AL Amyloidosis and multiple myeloma",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "121a95bf-b39f-4f50-b7d1-f7d3a325321e",
      "evidence": "Slides 7-8 highlight the limitations of current CAR-T therapies",
      "position": 0,
      "objective": "What is the cost of inaction for current CAR-T therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}